Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Form 8-K--Settlement with Deutsche Bank
Reply New Message
Prev Message Back To Forum Threaded View Next Message

In the 1/4 .. they had only written off about 545,000....which was about 10%.... of the current outstanding ARS..(correction welcome....) so we will do better than 90%...

Period Ending May 31, 2010 Feb 28, 2010 Nov 30, 2009 Aug 31, 2009
Assets
Current Assets
Cash And Cash Equivalents 10,361 8,570 11,594 8,255
Short Term Investments 12 10 379 21
Net Receivables 1,746 2,768 661 763
Inventory 137 - 65 89
Other Current Assets 1,162 607 375 707
Total Current Assets 13,417 11,955 13,075 9,835
Long Term Investments 5,641 7,910 7,829 10,882
Property Plant and Equipment 37 46 121 137
Goodwill 643 643 643 1,739
Intangible Assets 1,722 1,791 1,860 5,597
Accumulated Amortization - - - -
Other Assets 43 41 42 42
Deferred Long Term Asset Charges 5,912 5,691 5,764 4,332
Total Assets 27,416 28,078 29,333 32,565
Liabilities
Current Liabilities
Accounts Payable 786 558 815 773
Short/Current Long Term Debt - - - -
Other Current Liabilities 156 146 20 24
Total Current Liabilities 942 704 835 797
Long Term Debt 3,122 3,102 3,082 3,062
Other Liabilities - - 151 907
Deferred Long Term Liability Charges - - - -
Minority Interest - - - -
Negative Goodwill - - - -
Total Liabilities 4,064 3,805 4,068 4,767
Stockholders' Equity
Misc Stocks Options Warrants - - - -
Redeemable Preferred Stock - - - -
Preferred Stock - - - -
Common Stock (14,081) 4 4 4
Retained Earnings (39,562) (38,552) (37,614) (34,867)
Treasury Stock - (14,016) (13,891) (13,856)
Capital Surplus 77,241 77,229 77,156 77,047
Other Stockholder Equity (247) (393) (391) (530)
Total Stockholder Equity 23,352 24,272 25,265 27,798
Net Tangible Assets $20,987 $21,838 $22,762 $20,461
2 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply